SecBot SecBot
SECBOTREPLAY Home › Report › URGN

URGN · UroGen Pharma announced the first patient dosed in a Phase 1 trial of…

UroGen Pharma Ltd. · PRESS-RELEASE filed Nov 2, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 2, 2026 at 08:00 ET

UroGen Pharma announced the first patient dosed in a Phase 1 trial of UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial evaluates safety, tolerability, and pharmacokinetics of intravesical administration. This is an early-stage clinical milestone with no efficacy data yet, and the formulation being tested does not use UroGen's proprietary RTGel technology.

  • First patient dosed in Phase 1, open-label, dose-escalation trial of UGN-501 for NMIBC.
  • UGN-501 is an investigational next-generation oncolytic virus designed for direct tumor cell destruction and anti-tumor immune activation.
  • The Phase 1 trial will determine the recommended Phase 2 dose in adults with recurrent NMIBC (high-grade Ta/T1, CIS, or low-grade Ta/T1).
  • The formulation in this Phase 1 trial is aqueous and does not contain UroGen's proprietary RTGel technology.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access